Sinovac COVID vaccine shows modest efficacy against SARS-CoV-2 infection in children 3 to 5 years

In a new study under consideration at a Nature Portfolio Journal and published on the preprint server Research Square*, researchers investigated the efficacy of CoronaVac, a coronavirus disease 2019 (COVID-19) vaccine developed by Sinovac Biotech, in children aged three to five years. The findings of this study reveal that a two-dose regimen of the vaccine is highly effective in preventing severe COVID-19, whereas this vaccine regimen is modestly effective in preventing infection.